Improving anxiety-induced insomnia with lavender oil
New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.
Pharmaceutical-quality lavender oil has a significant anxiolytic (anxiety relieving) effect and improves insomnia when taken orally as a daily capsule, new data shows.
Disturbed sleep is a prevalent symptom in anxiety disorders and a key diagnosis criterion for subthreshold and generalised anxiety disorders (GAD). It is estimated that more than two thirds of patients with GAD suffer from insomnia, with even higher rates amongst the elderly, causing a detrimental effect on patients’ daily living skills and quality of life. In 80% of patients with diagnosed anxiety disorders, symptoms of insomnia appear simultaneously with anxiety symptoms(5) highlighting the importance of targeting insomnia in the treatment of anxiety.
Pharmacological anxiety treatments such as benzodiazepines carry a sedating effect. Although some patients may see a short-term improvement in sleep, common side effects of benzodiazepine use include daytime drowsiness and rebound insomnia – further intensifying sleep disturbances. Benzodiazepines can also cause a physical dependence and withdrawal reaction when taken for longer than the recommended 4 weeks, a common withdrawal symptom is insomnia making it hard for patients to break the anxiety-insomnia cycle.
A mediation analysis by researchers from the Universities of Zurich and Basel published this month in the Journal of Psychiatric Research, found that 98.4% of patients saw an improvement in anxiety-related sleep disturbances when taking a daily capsule of pharmaceutical quality lavender oil vs placebo. The results indicate that pharmaceutical quality lavender oil exerts a secondary sleep improving effect almost exclusively through its anxiety-relieving action rather than by sedation(.
Pharmaceutical quality lavender oil capsules are shown to decrease excessive neurotransmitter activity, reducing overstimulation and hyperactivity of the nervous response - improving symptoms of mild anxiety. More than 15 clinical trials show that a daily lavender oil capsule can be AS EFFECTIVE as commonly used anti-anxiety medication, including the benzodiazepine lorazepam prescribed in GAD without the risk of sedation, dependency or withdrawal.
Professor of Psychiatry, Professor Hans-Peter Volz comments: ‘’This is a positive development for anxiety. Research demonstrates that the lavender oil capsules reduce both physical and psychological symptoms of anxiety (including sleep disturbances), without issues such as sedation, addiction or withdrawal. Lavender oil capsules provide a promising alternative treatment option to prescription drugs for subthreshold anxiety sufferers.”
The anxiety-relieving effects of uniquely prepared, pharmaceutical quality lavender oil are available only in Kalms Lavender One-A-Day Capsules.
Nicky Lidbetter, CEO of Anxiety UK states: ‘’Anxiety is one of the most prevalent mental health conditions in the UK - one in five people report feeling anxious a lot or all of the time; and more than 45 million working days have been lost due to anxiety (combined with depression and stress) in the past three years. We welcome a range of treatment and support options, including the Kalms Lavender One-a-Day capsule and other non-prescription options such as talking therapies.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance